

## Supplementary Materials

Table 1. Description of antibodies

Figure 1. Effect of mycalamide A on cell viability of HeLa cells, detected by the cytotoxicity assay (MTS test)

Figure 2A.  $^1\text{H}$  NMR spectrum of mycalamide A in  $\text{CD}_3\text{OD}$  (0–6.0 ppm)

Figure 2B.  $^1\text{H}$  NMR spectrum of mycalamide A in  $\text{CD}_3\text{OD}$  (crop 0–1.8 ppm)

Figure 2C.  $^1\text{H}$  NMR spectrum of mycalamide A in  $\text{CD}_3\text{OD}$  (crop 1.8–2.7 ppm)

Figure 2D.  $^1\text{H}$  NMR spectrum of mycalamide A in  $\text{CD}_3\text{OD}$  (crop 3.0–4.0 ppm)

Figure 2E.  $^1\text{H}$  NMR spectrum of mycalamide A in  $\text{CD}_3\text{OD}$  (crop 4.0–4.9 ppm)


Figure 2F.  $^1\text{H}$  NMR spectrum of mycalamide A in  $\text{CD}_3\text{OD}$  (crop 5.0–6.0 ppm)

Figure 3.  $^{13}\text{C}$  NMR spectrum of mycalamide A in  $\text{DMSO-}d_6$


**Table 1.** Description of antibodies.

Antibodies	Clonality	Source	Cat.-No.	Dilution Used	Manufacturer
anti- $\alpha$ -Tubulin	mAb	mouse	T5168	1:5000	Sigma-Aldrich
anti- $\beta$ -actin	mAb	mouse	CP01	1:10000	Calbiochem
anti-caspase-3	mAb	rabbit	#9665	1:1000	Cell Signaling
anti-ERK	mAb	mouse	#9107	1:2000	Cell Signaling
anti-JNK	mAb	rabbit	#9258	1:1000	Cell Signaling
anti-p38	mAb	rabbit	#9212	1:1000	Cell Signaling
anti-phospho-ERK	mAb	rabbit	#4377	1:1000	Cell Signaling
anti-phospho-JNK	mAb	rabbit	#4668	1:1000	Cell Signaling
anti-phospho-p38	mAb	rabbit	#4511	1:1000	Cell Signaling
anti-mouse IgG-HRP		sheep	NXA931	1:10000	GE Healthcare
anti-rabbit IgG-HRP		goat	#7074	1:5000	Cell Signaling


**Figure 1.** Cell viability of HeLa cells under treatment with different concentrations of mycalamide A. Cytotoxicity was determined using the MTS method. Statistically significant differences (determined by *t*-test) between treated and control cells are indicated as follows: \*\*  $p < 0.01$ , \*\*\*  $p < 0.005$ .





**Figure 2A.**  $^1\text{H}$  NMR spectrum of mycalamide A in  $\text{CD}_3\text{OD}$  (0–6.0 ppm).



**Figure 2B.**  $^1\text{H}$  NMR spectrum of mycalamide A in  $\text{CD}_3\text{OD}$  (crop 0–1.8 ppm).



**Figure 2C.**  $^1\text{H}$  NMR spectrum of mycalamide A in  $\text{CD}_3\text{OD}$  (crop 1.8–2.7 ppm).**Figure 2D.**  $^1\text{H}$  NMR spectrum of mycalamide A in  $\text{CD}_3\text{OD}$  (crop 3.0–4.0 ppm).



**Figure 2E.**  $^1\text{H}$  NMR spectrum of mycalamide A in  $\text{CD}_3\text{OD}$  (crop 4.0–4.9 ppm).**Figure 2F.**  $^1\text{H}$  NMR spectrum of mycalamide A in  $\text{CD}_3\text{OD}$  (crop 5.0–6.0 ppm).

Figure 3. <sup>13</sup>C NMR spectrum of mycalamide A in DMSO-d<sub>6</sub>.

